{"entity":{"id":"hld-0915","kind":"drug","name":"HLD-0915 (JNJ-101556143)","aka":["HLD-0915","JNJ-101556143"],"tldr":"HLD-0915 (JNJ-101556143) is an experimental oral heterobifunctional small molecule from Halda Therapeutics, in phase 1 trials for metastatic prostate cancer.","summary":"HLD-0915 (JNJ-101556143) (HLD-0915, JNJ-101556143) is an oral heterobifunctional small molecule (RIPTAC) from Halda Therapeutics, with Johnson & Johnson as acquirer. A once-daily oral therapy built on the RIPTAC platform, which brings a tumour-specific protein together with a protein the cell needs to survive, to kill cancer cells selectively and overcome resistance. Its furthest stage is phase 1, for metastatic prostate cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1/2 NCT06800313 recruiting (sponsor Janssen Research & Development), and an arm in NCT06095089 (Janssen combination study). Johnson & Johnson completed the acquisition of Halda on 29 December 2025. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Halda Therapeutics: medicaldialogues.in","url":"https://medicaldialogues.in/amp/news/industry/pharma/jnj-completes-acquisition-of-halda-therapeutics-its-novel-platform-for-cancer-treatment-161646"},{"label":"Halda Therapeutics: indianpharmapost.com","url":"https://www.indianpharmapost.com/news/johnson-johnson-completes-305-billion-acquisition-of-halda-therapeutics-18745"},{"label":"Halda Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT06095089"},{"label":"ClinicalTrials.gov: trials of HLD-0915","url":"https://clinicaltrials.gov/search?intr=HLD-0915"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["halda-therapeutics","johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06800313","nct06095089"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"HLD-0915","modality":"Oral heterobifunctional small molecule (RIPTAC)","mechanism":"A once-daily oral therapy built on the RIPTAC platform, which brings a tumour-specific protein together with a protein the cell needs to survive, to kill cancer cells selectively and overcome resistance.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/hld-0915/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"halda-therapeutics","kind":"company","name":"Halda Therapeutics","route":"/companies/halda-therapeutics/"},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}],"trial":[{"id":"nct06095089","kind":"trial","name":"A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer","route":"/trials/nct06095089/"},{"id":"nct06800313","kind":"trial","name":"Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer","route":"/trials/nct06800313/"}]}}